Details of the Drug

General Information of Drug (ID: DMEAOYJ)

Drug Name

Ponesimod

Synonyms

854107-55-4; UNII-5G7AKV2MKP; 5G7AKV2MKP; CHEMBL1096146; Ponesimod [USAN:INN]; Ponesimod,ACT-128800; Ponesimod (ACT-128800); GTPL9320; SCHEMBL15477937; SCHEMBL15477934; DTXSID50234631; MolPort-035-681-391; MolPort-046-033-541; EX-A1417; ZINC34509627; s8241; BDBM50316768; AKOS022180266; DB12016; Compound 8bo [PMID:20446681]; HY-10569; KB-72962; AS-35140; AJ-89002; (2Z,5Z)-5-(3-Chloro-4-((2R)-2,3-dihydroxypropoxy)phenylmethylidene)-3-(2-methylphenyl)-2-(propylimino)-1,3-thiazolidin-

Indication

Disease Entry	ICD 11	Status	REF
Multiple sclerosis	8A40	Approved	[1]
Psoriasis vulgaris	EA90	Phase 2	[2]

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

461

Topological Polar Surface Area (xlogp)

4.6

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 3872 mcgh/L [3]
Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 109 mcg/L [3]
Absorption Tmax: The time to maximum plasma concentration (Tmax) is 4 h [3]
Clearance: The clearance of drug is 3.8 L/h [3]
Elimination: 57.3-79.6% of a radiolabelled oral dose is recovered in the feces, with 16-26% as the unmetabolized parent compound and 22% as the M12 metabolite [4]
Half-life: The concentration or amount of drug in body reduced by one-half in 33 hours [3]
Metabolism: The drug is metabolized via the CYP2J2, CYP3A4, CYP3A5, CYP4F3A, and CYP4F12 to the M12 metabolite [4]
Vd: The volume of distribution (Vd) of drug is 160 L [3]

Chemical Identifiers

Formula: C23H25ClN2O4S
IUPAC Name: (5Z)-5-[[3-chloro-4-[(2R)-2,3-dihydroxypropoxy]phenyl]methylidene]-3-(2-methylphenyl)-2-propylimino-1,3-thiazolidin-4-one
Canonical SMILES: CCCN=C1N(C(=O)/C(=C/C2=CC(=C(C=C2)OC[C@@H](CO)O)Cl)/S1)C3=CC=CC=C3C
InChI: InChI=1S/C23H25ClN2O4S/c1-3-10-25-23-26(19-7-5-4-6-15(19)2)22(29)21(31-23)12-16-8-9-20(18(24)11-16)30-14-17(28)13-27/h4-9,11-12,17,27-28H,3,10,13-14H2,1-2H3/b21-12-,25-23?/t17-/m1/s1
InChIKey: LPAUOXUZGSBGDU-ULCCENQXSA-N

Cross-matching ID

PubChem CID: 11363176
CAS Number: 854107-55-4
DrugBank ID: DB12016
TTD ID: D0Y4SI

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Sphingosine-1-phosphate receptor 1 (S1PR1)	TT9JZCK	S1PR1_HUMAN	Agonist	[1]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
2	ClinicalTrials.gov (NCT00852670) ACT-128800 in Psoriasis. U.S. National Institutes of Health.
3	FDA Approved Drug Products: Ponvory (Ponesimod) Oral Tablet
4	Lade JM, Avery LB, Bumpus NN: Human biotransformation of the nonnucleoside reverse transcriptase inhibitor rilpivirine and a cross-species metabolism comparison. Antimicrob Agents Chemother. 2013 Oct;57(10):5067-79. doi: 10.1128/AAC.01401-13. Epub 2013 Aug 5.
5	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
6	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
7	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
8	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9	Sphingosine 1-Phosphate Receptor Modulators in Multiple Sclerosis. CNS Drugs. 2015 Jul;29(7):565-75.
10	Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov. 2013 Sep;12(9):688-702.
11	Exploration of amino alcohol derivatives as novel, potent, and highly selective sphingosine-1-phosphate receptor subtype-1 agonists. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2520-4.
12	ASP4058, a novel agonist for sphingosine 1-phosphate receptors 1 and 5, ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile. PLoS One. 2014 Oct 27;9(10):e110819.